Our patented strategies improve dissolution and oral bioavailability of common therapeutics and are available for partnering or out-licensing.
Prodrug and Formulation Technologies
Unmet Need
Many current and emerging drug therapies suffer from poor PK/PD profiles and poor bioavailability. This can result in a less desirable route of administration, a complicated oral dosing regimen, unwanted side effects, or the complete discontinuation of product development.
Solution
TSRL, Inc. has developed drug delivery technologies to improve dose response, increase solubility, and reduce toxicity associated with extended release drugs. Our extended release formulation provides a PK/PD rational to reduce dose and toxicity of common disease states, including:
- Cholesterol Synthesis
- Cardiovascular Disease
- Asthma Bronchial
- Peptic Ulcer Disease
- Gastric Secretion
Rational for improvement in PK/PD:
- Circadian Rhythm: Night time maximum
- Reduction of Metabolism: Positional expression of P450 within intestine
- Formulation: Match maximum activity, delayed release to reduce metabolism, reduce dose and toxicity
Supported Intellectual Property (IP)
Supported IP within our drug delivery portfolio:
Name of Patent/Application | Patent/App. No. | Filing Date | Expiration Date |
---|---|---|---|
Controlled Release of Drugs | 6669954 | 1/10/2002 | 1/24/2021 |
Short Peptide Carrier System for Cellular Delivery of Agent | 7176185 | 11/24/2004 | 1/10/2025 |
Methods & Composition of Extended Delivery of Water Insoluble Drugs | 8535716 | 4/1/2005 | 4/7/2033 |
Supported IP within our antiviral prodrug portfolio:
Supported Intellectual Property | App/Patent No. | Filing Date | Expiration Date |
---|---|---|---|
Cidofovir Peptide Conjugates as Prodrugs | 7511051 | 7/1/2005 | 3/12/26 |
Phosphonyl Ester Conjugates as Prodrugs | 8063209 | 3/16/2009 | 10/13/25 |
Tyrosine-based Prodrugs of Antiviral Agents | 8940313 | 4/23/2011 | 5/27/31 |
Prodrugs of Neuraminidase Inhibitors | 9181281 | 11/26/2013 | 11/26/2033 |
For more information, contact Business Development at bd@tsrlinc.com